- Home
- ETV vs FTRE Comparison
ETV vs FTRE Comparison
Compare ETV & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- FTRE
- Stock Information
- Founded
- ETV 2005
- FTRE 1996
- Country
- ETV United States
- FTRE United States
- Employees
- ETV N/A
- FTRE N/A
- Industry
- ETV Investment Managers
- FTRE Medical Specialities
- Sector
- ETV Finance
- FTRE Health Care
- Exchange
- ETV Nasdaq
- FTRE Nasdaq
- Market Cap
- ETV 1.7B
- FTRE 1.9B
- IPO Year
- ETV N/A
- FTRE N/A
- Fundamental
- Price
- ETV $14.33
- FTRE $17.69
- Analyst Decision
- ETV
- FTRE Hold
- Analyst Count
- ETV 0
- FTRE 11
- Target Price
- ETV N/A
- FTRE $23.30
- AVG Volume (30 Days)
- ETV 252.5K
- FTRE 944.5K
- Earning Date
- ETV 01-01-0001
- FTRE 03-10-2025
- Dividend Yield
- ETV 8.75%
- FTRE N/A
- EPS Growth
- ETV N/A
- FTRE N/A
- EPS
- ETV N/A
- FTRE N/A
- Revenue
- ETV N/A
- FTRE $2,975,600,000.00
- Revenue This Year
- ETV N/A
- FTRE N/A
- Revenue Next Year
- ETV N/A
- FTRE $1.09
- P/E Ratio
- ETV N/A
- FTRE N/A
- Revenue Growth
- ETV N/A
- FTRE 2.80
- 52 Week Low
- ETV $11.05
- FTRE $16.53
- 52 Week High
- ETV $13.50
- FTRE $41.02
- Technical
- Relative Strength Index (RSI)
- ETV 52.14
- FTRE 39.63
- Support Level
- ETV $13.89
- FTRE $16.94
- Resistance Level
- ETV $14.45
- FTRE $18.52
- Average True Range (ATR)
- ETV 0.17
- FTRE 0.98
- MACD
- ETV -0.01
- FTRE -0.10
- Stochastic Oscillator
- ETV 73.33
- FTRE 22.59
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.